



Original article

Structural determinants of resveratrol for cell proliferation inhibition potency: Experimental and docking studies of new analogs

Frédéric Mazué^a, Didier Colin^a, Jessica Gobbo^a, Maria Wegner^a, Antonio Rescifina^c, Carmela Spatafora^c, Dominique Fasseur^b, Dominique Delmas^a, Philippe Meunier^b, Corrado Tringali^c, Norbert Latruffe^{a,*}^aINSERM U 866; University of Burgundy, Laboratory of Biochemistry of Metabolism and Nutrition, 6, Bd Gabriel, F-21000 Dijon, France^bICMUB-UMR CNRS 5260, University of Burgundy, Institute of Molecular Chemistry, Ave Savary, F-21000 Dijon, France^cUniversità degli Studi di Catania, Dipartimento di Scienze Chimiche, Viale Andrea Doria 6, I-95125 Catania, Italy

ARTICLE INFO

Article history:

Received 10 November 2009

Received in revised form

15 March 2010

Accepted 16 March 2010

Available online 25 March 2010

Keywords:

Resveratrol

Polymethoxy-stilbenes

Tubulin polymerization

Colon cancer

Docking studies

ABSTRACT

Resveratrol is the subject of intense research because of the abundance of this compound in the human diet and as one of the most valuable natural chemopreventive agents. Further advances require new resveratrol analogs be used to identify the structural determinants of resveratrol for the inhibition potency of cell proliferation by comparing experimental and docking studies. Therefore, we synthesized new *trans*/(*E*)- and *cis*/(*Z*)-resveratrol – analogs not reported to date – by modifying the hydroxylation pattern of resveratrol and a double bond geometry. We included them in a larger panel of 14 molecules, including (*Z*)-3,5,4'-trimethoxystilbene, the most powerful molecule that is used as reference. Using a docking model complementary to experimental studies on the proliferation inhibition of the human colorectal tumor SW480 cell line, we show that methylation is the determinant substitution in inhibition efficacy, but only in molecules bearing a *Z* configuration. Most of the synthetic methylated derivatives (*E* or *Z*) stop mitosis at the M phase and lead to polyploid cells, while (*E*)-resveratrol inhibits cells at the S phase. Docking studies show that almost all of the docked structures of (*Z*)-polymethoxy isomers, but not most of the (*E*)-polymethoxy isomers substantially overlap the docked structure of combretastatin A-4, taken as reference ligand at the colchicine–tubulin binding site.

© 2010 Elsevier Masson SAS. All rights reserved.

1. Introduction

Recent evidence suggests that the use of resveratrol, a well-known polyphenol that is abundant in the human diet, in combination with drugs, ionizing radiation, or cytokines can be effective in the sensitization to apoptosis. Natural *trans*-resveratrol [(*E*)-3,5,4'-trihydroxystilbene] targets a wide variety of intracellular mechanisms involved in the pathways leading to malignancy. In various *in vitro* and *in vivo* models, this polyphenolic compound has proven to be capable of retarding or preventing the various steps of carcinogenesis [1]. This protective effect could be related to the ability of resveratrol to arrest cell cycle progression [2,3] or to trigger tumor cell death by apoptosis [4,5]. Recently, resveratrol has been shown to behave also as a sensitizer of anticancer drugs such as 5-fluoro-uracil [6] and paclitaxel [7], radiation [8], and cytokines such as TRAIL [5].

Nevertheless, various studies have documented that stilbenes and flavonoids, despite efficient absorption by the organism, unfortunately have low bioavailability, glucuronidation and sulfation being limiting factors [9–11]. We have recently developed acetylated forms of resveratrol and oligomers, showing that acetylation of resveratrol inhibits cancer cell proliferation in the same manner as resveratrol [12–14]. In contrast, the isomerization of molecules and the methylation of hydroxyl groups change the cell molecular targets and are essential to strengthen the efficiency of resveratrol derivatives for blocking the cell cycle [15–17], suggesting that polymethoxy-stilbenes and related compounds are a subgroup of resveratrol analogs showing promising antitumor properties (see for review [18]). In addition, *in vivo* studies indicate that polymethoxy-stilbenes undergo a different metabolic conversion and have a higher bioavailability than resveratrol.

While previous studies already reported the synthesis of polymethoxy-stilbene analogs [18], especially highlighting (*Z*)-3,5,4'-trimethoxystilbene, which exhibits strong antiproliferative activity by acting as an inhibitor of tubulin polymerization [19], the structure–activity relationship remains unclear, for example, the methyl

* Corresponding author.

E-mail address: latruffe@u-bourgogne.fr (N. Latruffe).

position and number, double bond configuration, or the additional hydroxyl group. The originality of our work is based on two strategies: synthesis of three new resveratrol analogs as yet unpublished (compounds **6**, **10** and **14**) and the use of docking modeling studies and their comparison with experimental data from the human colorectal tumor SW480 cell line to identify biological targets. For a coherent approach to critical methylation resveratrol analogs and for a better understanding, we tested a larger panel of molecules from already published resveratrol analogs including (*Z*)-3,5,4'-trimethoxystilbene (compound **4**), the most powerful molecule. Thus, with a proper synthetic methodology, previously employed for some of the compounds reported here [20] and exemplified in Fig. 1, a library of resveratrol analogs was obtained from (*E*)- and (*Z*)-resveratrol (Fig. 1, compounds **1** and **2**). Both (*E*)- and (*Z*)-isomers for each substrate were prepared. In the first group, the 3,5,4'-hydroxyl groups of resveratrol were replaced with methoxy groups (compounds **3** and **4**) and a further hydroxyl group was inserted at position 2 (compounds **5** and **6**); a second group was represented by 3,5,3',5'-tetramethoxy-stilbenes (compounds **7** and **8**) also bearing a hydroxyl group in C-2 (compounds **9** and **10**); in a third group of 3,5,3',4'-tetramethoxy-stilbenes, the two rings were asymmetrically substituted (compounds **11** and **12**), and also in this case the 2-hydroxy analogs were prepared (compounds **13** and **14**). We established that the number of methyl groups of resveratrol is crucial for determining the inhibitory properties of colorectal cancer cell proliferation and in cell cycle arrest. The strongest effect

depends on *Z*-stereochemistry. The presence of a supplementary hydroxyl group decreases the efficiency of the antiproliferative properties of resveratrol analogs. Interestingly, (*Z*)-isomer treatments lead to a polyploidy phenomenon in colon cancer cells. Using a computational docking approach, we show that *Z*-isomers, apart from (*Z*)-resveratrol and (*Z*)-tetramethoxy-stilbene, can be incorporated into the colchicine site of tubulin. All (*Z*)-isomers substantially overlap the docked structure of combretastatin A-4 (**15**), taken as reference.

2. Material and methods

2.1. General

The ¹H and ¹³C NMR spectra were run on a Varian Unity Inova spectrometer at 500 and 125 MHz, respectively, in CDCl₃ or C₆D₆ solutions with TMS as internal standard. Mass spectra were recorded in ESI positive mode on a Micromass ZQ2000 spectrometer (Waters). All reactions were monitored by TLC on commercially available precoated plates (silica gel 60 F254) and the products were visualized with cerium sulfate solution. A silica gel 60 was employed for column chromatography. Resveratrol (**1**) was purchased from Sigma; *m*-chloroperbenzoic acid (*m*-CPBA) 99% assay was obtained by washing the commercial 77% material (Aldrich) with a phosphate buffer at pH 7.5 and drying the residue under reduced pressure.




Fig. 1. Structure of (*E*)/*trans*-resveratrol (A), (*Z*)/*cis*-resveratrol (B) related analogs and combretastatin A-4 (C).

The known compounds **3**, **5**, **7**, **9**, **11**, and **13** were synthesized as previously reported, based on an Arbuzov rearrangement followed by the Horner–Emmons–Wadsworth reaction [20]. Compound **4** was prepared by the classic Wittig reaction: 4-methoxybenzyl-triphosfonium chloride was reacted with 3,5-dimethoxybenzaldehyde and BuLi in THF to afford **4**. Spectral data of the known compounds are in perfect agreement with those obtained previously [20]. Calculated log *D* values were obtained with ACD/labs Log *D* program version 11.

2.2. Photo-isomerization

Irradiation experiments were conducted in a 200-mL quartz vessel using a Rayonet photochemical reactor equipped with a variable number of “black light” phosphor lamps with emission in the 310 to 390nm range and a maximum at 350 nm. The fluence rate at the irradiation position was measured to be 5 mW·cm⁻². A 2 × 10⁻⁴ M solution (200 mL) of each compound (**1**, **3**, **7**, and **11**) in ethanol was irradiated in the reactor for 10 min under nitrogen bubbling. The irradiated solution was then reduced to a small volume under vacuum and charged onto the appropriate silica gel column to separate the (*Z*)-product from the residual (*E*)-isomer. All photo-isomerizations were obtained with 78–82% conversion, based on ¹H NMR measurements. Spectral data of the **2**, **4**, **8**, and **12** compounds obtained are in perfect agreement with those previously reported [17,21–23].

2.3. Chemical procedure of hydroxylation

The compounds **6**, **10**, and **14** were synthesized as follows: a solution of *m*-CPBA in CH₂Cl₂ (0.150 mmol/mL) was added to a stirred solution of the substrate in CH₂Cl₂ (0.105 mmol/mL) at room temperature. The reaction mixtures were then washed with a NaHSO₃ solution and subsequently with saturated aqueous NaHCO₃. The organic layer was dried (Na₂SO₄), filtered, and concentrated *in vacuo*; the residues were submitted to flash-chromatography on a 3 × 25 cm silica gel column, eluted with EtOAc in *n*-hexane (from 0% to 30%).

(Z)-2-Hydroxy-3,5,4'-trimethoxystilbene (6): EI-MS *m/z* 285 [M-H]⁻; ¹H NMR (CDCl₃): δ 3.53 (s, 3H, 4'-OCH₃); 3.77 (s, 3H, 5-OCH₃); 3.86 (s, 3H, 3-OCH₃); 5.35 (s, 1H, OH); 6.33 (d, 1H, *J* = 2.0 Hz, H-4); 6.38 (d, 1H, *J* = 2.0 Hz, H-6); 6.57 (d, 1H, *J* = 12.0 Hz, H-α); 6.61 (d, 1H, *J* = 12 Hz, H-β); 6.75 (d, 2H, *J* = 7.5 Hz, H-3' and H-5'); 7.23 (d, 2H, *J* = 7.5 Hz, H-2' and H-6'). ¹³C NMR (CDCl₃): δ 158.7, 152.4, 147.0, 137.6, 130.4, 128.6, 127.4, 123.5, 122.9, 114.2, 100.5, 98.8, 56.2, 55.9, 55.5.

(Z)-2-Hydroxy-3,5,3',5'-tetramethoxystilbene (10): EI-MS *m/z* 315 [M-H]⁻; ¹H NMR (CDCl₃): δ 3.52 (s, 3H, 5-OCH₃); 3.65 (s, 6H, 3',5'-OCH₃); 3.86 (s, 3H, 3-OCH₃); 5.38 (s, 1H, OH); 6.31 (s, 1H, H-4'); 6.33 (s, 1H, H-6); 6.37 (s, 1H, H-4); 6.47 (s, 2H, H-2' and H-6'); 6.60 (d, 1H, *J* = 12.5 Hz, H-α); 6.71 (d, 1H, *J* = 12.5 Hz, H-β). ¹³C NMR (CDCl₃): δ 159.8, 153.9, 146.9, 139.2, 137.2, 131.0, 123.9, 122.5, 104.2, 100.0, 99.1, 56.1, 55.7, 55.4.

(Z)-2-Hydroxy-3,5,3',4'-tetramethoxystilbene (14): EI-MS *m/z* 315 [M-H]⁻; ¹H NMR (CDCl₃): δ 3.35 (s, 3H, 4'OCH₃); 3.63 (s, 3H, 3'-OCH₃); 3.85 (s, 6H, 3,5-OCH₃); 5.36 (s, 1H, OH); 6.35 (d, 1H, *J* = 2.5 Hz, H-4); 6.38 (d, 1H, *J* = 2.5 Hz, H-6); 6.59 (bs, 2H, H-α and H-β); 6.74 (d, 1H, *J* = 8.5 Hz, H-3); 6.85 (d, 1H, *J* = 8.5, H-2') overlapped with 6.74 (d, 1H, *J* = 2 Hz, H-6'). ¹³C NMR (CDCl₃): δ 151.9, 150.1, 149.8, 148.2, 137.6, 130.6, 129.9, 123.7, 122.1, 121.1, 111.7, 110.7, 104.3, 98.9, 56.2, 55.7, 55.5, 55.4.

The spectral data of already published resveratrol analogs are in agreement with those reported in the literature [24].

2.4. Biological methods

2.4.1. Proliferation and cytotoxicity assays

The human colon carcinoma cell line SW480 was cultured in RPMI-Medium with 10% fetal bovine serum and 1% antibiotics. Proliferation inhibition assays were performed in 24-well plates in triplicate, and each experiment was conducted three times. In all, 30,000 cells were seeded per well and after 24 h were treated with media containing either 0.1% dimethylsulfoxide with (*E*)-resveratrol, or with resveratrol derivatives, or with 0.1% dimethylsulfoxide as control. After 24, 48, and 72 h, adherent cells collected by trypsinization and detached cells were labeled in 1 mL medium containing 1 μg/mL of propidium iodide. Cells were counted using a Cyflow green flow cytometer (Partec, Münster). Dead cells were distinguished from viable cells by incorporation of propidium iodide. Subsequently, 48h IC₅₀ values were determined by performing 1 nM–100 μM treatments and the IC₅₀ values were obtained after parametric regressions on the percentages of viable cells versus the control.

2.4.2. Cell cycle and DNA content analysis and microscopic examination of cell nuclei morphology

See the techniques previously used in [12–14].

2.5. Computational docking studies

In view of the structural similarities of (*Z*)-polymethoxy stilbenes with combretastatin, we also investigated the binding model of all (*E*)- and (*Z*)-isomers **1–14** in comparison with combretastatin A-4 to delineate their structure–activity relationships (SARs). Thus, given that the cytotoxicity mechanism of combretastatin and related structures has been shown to involve the inhibition of tubulin polymerization by binding tubulin at the colchicine binding site [25], we conducted molecular docking simulations of all stilbene analogs into this pocket [26]. The reported 3D structure of the tubulin–DAMA–colchicine–stathmin-like domain complex was retrieved from the Protein Data Bank (<http://www.rcsb.org/PDB>; code 1SAO), but it has a resolution of only 3.58 Å and therefore requires considerable computational effort before models derived from it can be considered “all-atom” [27]. Thus, the stathmin-like domain, the C and D subunits, and the DAMA–colchicine were removed from the model, the missing atoms on chain A residues Gln 35, Asp 47, Thr 51, Glu 55, Thr 56, Glu 77, Arg 221, Gln 285, Arg 308, Ile 335, Lys 336, Lys 338, Arg 339, Gln 342, and chain B residues His 37, Asn 59, Lys 124, Ser 126, Arg 215, Lys 218, Leu 219, Arg 322, Lys 326, Lys 338, Arg 369, Lys 372, Asp 437 were added and locally optimized. Then, using the MolProbity Web server [28], the hydrogen atoms were added and the orientations of the hydroxyl hydrogens from the Ser, Thr, and Tyr, the sulfhydryl orientations of Cys, and the methyls of Met amino acids were optimized; at the same time the positions of hydrogens on histidine, asparagine, and glutamine residues were assigned, ensuring suitable ionization states. Finally, the Gasteiger–Marsili charges [29] were assigned and the whole protein, with the combretastatin A-4 positioned in the place of the DAMA–colchicine ligand and aligned with the A-ring, and the three methoxyl groups were optimized to an energy gradient of 0.005 kcal·Å/mol with amber 96 force field [30].

3. Results

We compared the potency of resveratrol synthetic analogs toward the human colorectal tumor cell line SW480 by comparing two reference natural molecules, i.e., (*E*)-3,5,4'-Trihydroxystilbene (**1**) and (*Z*)-3,5,4'-Trihydroxystilbene (**2**) (Fig. 1); the (*E*)- and (*Z*)-isomers of the 3,5,4'-Trimethoxystilbene (**3** and **4**, respectively),

permethylated analogs of resveratrol, were also included in view of their previously reported high antiproliferative activity.

3.1. Antiproliferative activity toward SW480 colon cancer cell line

To compare the effect of resveratrol analogs on cell growth, SW480 cells were treated with molecules from our library and the antiproliferative activity of compounds **1**–**14** was determined as IC₅₀ (in μ M) and is reported in Table 1. The most active compounds, in order of decreasing potency, were the following: (*Z*)-3,5,4'-Trimethoxystilbene (**4**), 0.3 μ M > (*Z*)-2-Hydroxy-3,5,3',5'-Tetramethoxystilbene (**10**), 7 μ M > (*Z*)-3,5,3',4'-Tetramethoxystilbene (**12**), 9.5 μ M > (*Z*)-2-Hydroxy-3,5,3',4'-Tetramethoxystilbene (**14**), 10 μ M > (*Z*)-3,5,3',5'-Tetramethoxystilbene (**8**), 13 μ M > (*E*)-2-Hydroxy-3,5,3',5'-Tetramethoxystilbene (**9**), 17 μ M > (*E*)-Resveratrol (**1**), 20 μ M.

When compound **11** was compared with **7** (which is only different in the position of one methoxy group) it appeared to be less active. The same tendency was observed between (*E*)-tetramethoxy derivatives, i.e., **13** compared with **9**. For the derivatives with *trans* configuration, too, a slightly higher effect was seen with a methoxy group in another position (**12** > **8**, **10** > **14**). (*Z*)-3,5,3',4'-Tetramethoxystilbene (**12**) and (*Z*)-2-Hydroxy-3,5,3',4'-tetramethoxystilbene (**14**), two (*Z*)-tetramethoxystilbenes, were potent but they appeared to be less effective than the (*Z*)-trimethoxy analog **4** as a reference of the most potent resveratrol analog.

3.2. Cell cycle and DNA content

To further explore the mechanisms by which all these polyphenols exert their antiproliferative potencies, we studied their effects on the cell cycle distribution of SW480 cells. As shown in the top panel of Fig. 2A, percentages of cells were determined by electronic gating on cell populations according to their DNA content: the diploid cell cycle was divided into a 2n G₀/G₁ phase, a S phase of DNA replication ($2 < n < 4$), and a 4n G₂/M phase. Moreover, it should be noted that cancer cells, mainly colon cancer cells, are usually unstable and display >4n DNA content associated with polyploidy. Fig. 2A shows the flow cytometry diagrams obtained after 48h treatments of SW480 cells with all the compounds from our library at 30 μ M, a common concentration used to evaluate (*E*)-resveratrol anticancer potencies *in vitro*. Only compound **4**, which is highly toxic at 30 μ M, was used at 1 μ M for comparison. The synthetic histograms of the cell distribution in the different phases of the cell cycle are also shown in Fig. 2B.

Table 1
Potencies of resveratrol derivatives antiproliferative activities toward SW480 human colorectal cells after 48 h of treatment.

Compound	Number	IC ₅₀ (μ M)
A. IC ₅₀ of (<i>E</i>)-resveratrol derivatives		
(<i>E</i>)-Resveratrol	1	20 \pm 3
(<i>E</i>)-3,5,4'-Trimethoxystilbene	3	54 \pm 8
(<i>E</i>)-2-Hydroxy-3,5,4'-trimethoxystilbene	5	43 \pm 6
(<i>E</i>)-3,5,3',5'-Tetramethoxystilbene	7	48 \pm 7
(<i>E</i>)-2-Hydroxy-3,5,3',5'-tetramethoxystilbene	9	17 \pm 2
(<i>E</i>)-3,5,3',4'-Tetramethoxystilbene	11	100 \pm 15
(<i>E</i>)-2-Hydroxy-3,5,3',4'-tetramethoxystilbene	13	42 \pm 3
B. IC ₅₀ of (<i>Z</i>)-resveratrol derivatives		
(<i>Z</i>)-Resveratrol	2	90 \pm 12
(<i>Z</i>)-3,5,4'-Trimethoxystilbene	4	0.3 \pm 0.04
(<i>Z</i>)-2-Hydroxy-3,5,4'-trimethoxystilbene	6	18 \pm 2
(<i>Z</i>)-3,5,3',5'-Tetramethoxystilbene	8	13 \pm 2
(<i>Z</i>)-2-Hydroxy-3,5,3',5'-tetramethoxystilbene	10	7 \pm 2
(<i>Z</i>)-3,5,3',4'-Tetramethoxystilbene	12	9.5 \pm 2
(<i>Z</i>)-2-Hydroxy-3,5,3',4'-tetramethoxystilbene	14	10 \pm 2




Fig. 2. Effect of methoxyresveratrol analogs on SW480 cell cycle. Flow cytometry analysis of SW480 cells distribution in the cell cycle after 48 h treatments by resveratrol analogues (number). Diagrams show cell numbers against DNA content measurement by propidium iodide staining. Synthetic histograms of cell distribution among their cell cycle. Data are means \pm SD of a representative experiment among three independent. For experimental procedure, see material and methods.

Three types of compounds can be reported, according to their effects on cell cycle distribution: those that exert no effects and are essentially (*E*)-isomers plus (*Z*)-resveratrol (compounds **2**, **7**, **9**, **11**, **13**) with an average of 50% G₀/G₁ cells, 15% S cells, 25% 4n cells, and 10% >4n cells. Another compound is the well-known (*E*)-resveratrol by itself, which induces a strong S-phase arrest and a small increase of polyploidy. Finally, many compounds (especially (*Z*)-isomers, compounds **3**, **4**, **5**, **6**, **8**, **10**, **12**, **14**) completely disturb the diploid cell cycle, leading to the generation of polyploid cells, more precisely of tetraploid cells because of the loss of 2n cells and of the increase in 4n and 8n cells.

To have an overall view of the mechanisms involved in the polyploidization induced by most of the (*Z*)-isomers, we performed a time- and concentration-dependent analysis of the effects of (*Z*)-3,5,4'-trimethoxystilbene (**4**) as reference [19]. The antiproliferative activity of this compound occurred in a time- and dose-dependent manner as compared to (*E*)-resveratrol, and did not exert toxic effects at the highest concentration used (1 μM) (Fig. 3A). It was also noted that in contrast to (*E*)-resveratrol, there was no growth resurgence after 72 h. Moreover, at 1 μM (IC₅₀ = 0.3 μM), compound **4** did not seem to be more potent than 0.2 μM or 0.5 μM. Thus, cell cycle analyses after treatment with the same concentrations showed comparable results: 0.5 μM and 1.0 μM treatments led to exactly the same profile of cell cycle disruption with an increase of 4n and >4n cells (Fig. 3B). Nevertheless, 0.2 μM treatments exerted weaker effects than higher concentrations with regard to cell distribution in the cell cycle.

We then used microscopic analysis to illustrate the accumulation of polyploid cells after treatment with compound **4** (Fig. 3C). Hoechst staining allowed us to confirm that this (*Z*)-isomer leads to mitotic disturbances. Indeed, as compared to resveratrol treatment, which induces nuclear swelling, compound **4** inhibits cytokinesis resulting in endocycle and multinucleated cells (karyokinesis inhibition would have produced giant nuclei).

3.3. Binding model of (*E*)- and (*Z*)-stilbene isomers

Starting from the experimental data (presented in previous sections), we looked for possible relationships between structures of resveratrol analogs and their affinity to bind colchicine at the tubulin-binding site, responsible for mitosis inhibition and polyploidy, via a computational docking approach.

To validate the model, we docked combretastatin A-4 (Fig. 1C) and some structurally diversified combretastatin-like analogs that bind to colchicine at the tubulin binding site to compare their experimentally obtained IC₅₀ values with the calculated values. The results obtained (not reported here; see Supplementary Data) showed that the model is able to reproduce the IC₅₀ experimental values with a high precision that is, to our knowledge, the best obtained to date by docking methodology. The model was applied successively to compounds **1–14** and the results obtained, arranged in order of decreasing calculated activity, are presented in Table 2.

Although almost all the (*E*)-isomers were less active than the (*Z*)-isomers against the inhibition of SW480 cells, they were




Fig. 3. Inherent mechanisms of antiproliferative activity of compound **4**. **A**. Proliferation of SW480 cells treated with resveratrol (compound **1**) at 30 μM and compound **4** from 0.2 to 1.0 μM during 24, 48 and 72 h. Data are means ± SD of a representative experiment among three independent. For experimental procedure, see material and methods. **B**. Flow cytometry analysis of SW480 cells distribution in the cell cycle after 48 h treatments by compound **1** and **4** at indicated concentrations. Diagrams show cell numbers against DNA content measurement by propidium iodide staining. **C**. Microscopic analysis of SW480 cells left untreated (Ctl) or treated with 30 μM resveratrol (**1**) or with 0.5 μM of compound **4** for 48 h. Green fluorescence (Alexa 488) is due to actin immunostaining performed to see the shape of the cells. Blue fluorescence (Hoechst 33342) reveals nuclei. All the pictures have been taken with the same conditions and magnification (100×). This figure represents an example of three independent experiments. [For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.]

Table 2

Calculated and experimental binding affinity to colchicine site of tubulin for substituted stilbenes **1–14**.

Ligand	ΔG_{Bind} calcd. (kcal/mol)	IC ₅₀ calcd. (μM)
10	−7.87	1.69
6	−7.72	2.18
12	−7.53	3.00
4	−7.50	3.16 ^a
2	−7.27	4.66
1	−7.24	4.90
14	−7.14	5.80
9	−7.01	7.23
7	−7.01	7.23
8	−6.93	8.27
3	−6.82	9.96
5	−6.79	10.48
11	−6.72	11.79
13	−6.46	18.30

^a An experimental value of 4.00 is reported. See Schneider et al. [19].

integrated into the colchicine site of tubulin. Moreover, compounds **1**, **7**, and **9** showed a binding affinity comparable to that of compounds **14** and **8**; these data point out that the efficiency in the interaction with the receptor site, alone, is not sufficient to elucidate the anticancer potency, and many other factors, such as absorption, distribution, and metabolism, must be considered especially important in this case. However, some conclusions can be made from the docking results. All docked structures of (*Z*)-isomers, with the exception of compound **2**, which is moved down, and compound **8**, which is overturned, substantially overlap the docked structure of combretastatin A-4, taken as reference (Fig. 4A). Moreover, compounds **6** and **14** collocated the 3,5-dimethoxy groups of the A-ring in the same position of the corresponding combretastatin A-4 rings with the hydroxylic moiety, which engages a hydrogen bond with Ser B132 (not shown); conversely, compound **10**, which possesses the best affinity, has two *m*-methoxy groups in both the A- and B-rings so it could be arranged into two possible orientations with respect to combretastatin A-4. The best arrangement results from the B-ring overlapping with the A-ring of compound **15**, as shown in Fig. 4B. In this position, compound **10** establishes six hydrogen bonds with the tubulin receptor: 3'-methoxyl with the Cys B238 sulfhydryl, 5'-methoxyl with the Ser A132 hydroxyl, 2-hydroxyl with both carbonyl of Thr A133 and Asn B255, and 3-methoxyl with the Lys A67 ammonium and with Ala A134 amidic hydrogen (Fig. 4B). Finally, Fig. 4C shows how all (*E*)-isomers overlap compared with combretastatin A-4. Also, in this case all compounds are sufficiently aligned between them but not with combretastatin, with the exception of compounds **3** and **5**, which, possessing only one methoxyl in the B-ring, prefer to interact with the hydrophobic channel that joins the A and B subunits protruding to the A subunits. Interestingly, the three compounds with the 2-hydroxyl group are almost perfectly overlapping with the B-ring of the reference compound combretastatin.

The comparison between binding models of (*E*)- and (*Z*)-resveratrol isomers with regard to tubulin and cell proliferation inhibition potencies is presented in Table 3, with the following results:

- Almost all the (*Z*)-polymethoxy stilbenes were more active than the (*E*)-polymethoxy stilbenes. One exception may occur for compound **9**, but the difference is within the SD range of compound **6**. Conversely, (*E*)-resveratrol (**1**) is significantly more active than (*Z*)-resveratrol (**2**) notwithstanding that both showed a similar affinity for the tubulin pocket (similar IC₅₀ values calculated from docking). These data are in agreement

with our previous assumptions [15], i.e., that the mechanism of the antiproliferative activity of resveratrol seems to be different from that of polymethoxy-stilbenes, the latter probably being related to inhibition of tubulin.

- Among (*Z*)-polymethoxy stilbenes, 3,5,4'-trimethoxystilbene (**4**) is confirmed to be the most active compound by far. This result is also in perfect agreement with the data of Schneider et al. [19], who reported an IC₅₀ = 0.23 μM versus SW480 cells for **4**. This is partly in agreement with our docking results, indicating that compound **4** integrated well within the tubulin hydrophobic pocket but with a lower score than compounds **6**, **10**, and **12**. Nevertheless, **6** was (relative to **4**) scarcely hydrophobic (see calculated log *D* values) and this could explain the difference between tubulin fitting and *in vitro* activity: scarcely hydrophobic compounds (like resveratrol itself) could not reach the hydrophobic pocket of tubulin, regardless of their docking "score". Compound **4** was also more hydrophobic than **10** and **12**, and this is probably an important factor to target the tubulin site. Both compounds **6** and **10** were hydroxylated at C-2 and this structural detail seems important for tubulin fitting, but is probably an unfavorable factor in bioassays, perhaps because of easier metabolic conversion or air oxidation. It is known from the literature that **1** has a rapid metabolic conversion [31]. Compound **12** is probably in an intermediate situation, i.e., it has less tubulin affinity but it may be less sensitive to degradation.
- Compounds **8** and **14** were in a similar range of activity, which was partly confirmed by the docking data (Table 3). Analogously, the group of (*E*)-polymethoxy stilbenes with lower activity (**3**, **5**, **7**, **11**, **13**; experimental IC₅₀ values: 42–100 μM) do not fit well with the tubulin pocket (calculated IC₅₀ values: 7–18 μM).

4. Discussion

We compared two series of molecules starting from (*E*)-stereoisomer and its (*Z*)-counterpart. It must be noted that to date the use of (*Z*)-resveratrol has not been reported. Some of the compounds tested demonstrate much more potencies than the natural parent molecule. Compared with (*E*)-resveratrol, which leads to a cell growth arrest in S phase, the methylated derivatives stop cell proliferation by inducing G₂/M failures and also a polyploidization of the SW480 cell line. (*E*)-resveratrol derivatives also induce cancer cell apoptosis since sub-G₁ peaks were found during the flow cytometry analysis. Cell polyploidization, which can occur naturally to repair damaged DNA, is induced by all of the methylated compounds. (*Z*)-3,5,4'-trimethoxystilbene (**4**) has been described as an inhibitor of tubulin polymerization [31]. Inhibition leads to mitosis defect and cytokinesis impairment. The destiny of tetraploidy-induced cells is unknown; these cells could still proliferate and become more resistant [32] or die by mitotic catastrophe [33].

The study of synthetic (*E*)-resveratrol derivatives could offer a wide range of compounds that are potentially more active than (*E*)-resveratrol (about 66-fold for **4**), but these molecules seem to have a different way of delaying cancer cell growth.

Our team previously tested similar resveratrol analogs on various tumor cell lines: DU145 (androgen-nonresponsive human prostate cancer), LNCaP (androgen-responsive human prostate cancer tumor), M14 (human melanoma), and KB (human mouth epidermoid carcinoma) [15]. In all cell lines, results indicate a stronger effect of (*E*)-3,5,4'-trimethoxystilbene (**3**) than (*E*)-resveratrol, especially toward DU145 cells. The corresponding (*Z*)-trimethoxy analog **4** was very active toward the KB cell line but with a poor effect on M14 cells.




Fig. 4. Computational studies and binding model of (*E*)- and (*Z*)-stilbenes isomers. For part A and C, the binding models for all stilbenes were constructed using the combretastatin model [25] as a template and reference ligand in the binding site. Computational docking was carried out applying the Lamarckian genetic algorithm (LGA) implemented in AutoDock 4.0 [29]. For fine docking, we used the following parameters: grid spacing = 0.261 Å, number of runs = 100, npts = 50–60–50 centered on combretastatin A-4, ga_num_evals = 20,000,000, ga_pop_size = 150, and ga_num_generations = 27,000. A. Superposition of all (*Z*)-stilbene analogues docked at the colchicine-binding site. The docked structure of combretastatin A-4, represented in orange (tube rendering), is inserted for comparison. Only polar hydrogens are represented, for clarity. Ligands are rendered as sticks with the subsequent colour code: **2** yellow, **4** red, **6** green, **8** blue, **10** brown, **12** magenta and **14** cyan. B. Molecular docking result of compound **10** at the colchicine-binding site of tubulin. Only the amino acid residues within 4.5 Å around the inhibitor are shown for clarity. The ligand is represented with the carbon skeleton in brown with the only polar hydrogen. Dotted lines represent hydrogen bonds between ligand and receptor. The numerotation of amino acid residues is decremented by 3 unit for subunit A and 56 for subunit B respect to the original PDB file due to the strong manipulation and multiple file format conversions experienced. C. Superposition of all (*E*)-stilbene analogues docked at the colchicine-binding site. The docked structure of combretastatin A-4, represented in orange (tube rendering), is inserted for comparison. Only polar hydrogens are represented, for clarity. Ligands are rendered as sticks with the subsequent colour code: **1** yellow, **3** red, **5** green, **7** blue, **9** brown, **11** magenta and **13** cyan. [For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.]

Szekeres's group [34] reported on the influence of several (*E*)-resveratrol analogs on HT29 human colon cancer cell proliferation inhibition and apoptosis, and some results are similar to those obtained by our group, i.e., the poor effect of (*E*)-3,5,3',4'-tetramethoxystilbene (**11**) and blockade on G₀-G₁. Other results are conflicting; a strong effect of (*E*)-3,5,4'-trimethoxystilbene (**3**) on HT29 cells and a weaker effect on SW480 cells (our data). More generally, methylated resveratrol analogs, although nonantioxidant molecules, have a stronger effect than the parent molecule. Indeed, they inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappa B [35].

In summary, while (*E*)-resveratrol is considered to be a promising molecule for fighting cancer [36], synthetic resveratrol analogs could offer a wide range of compounds that are potentially more active than (*E*)-resveratrol. These molecules seem to have a different way of delaying cancer cell growth. Resveratrol inhibits cells in S phase, while most of the other synthetic derivatives stop mitosis or block it in an unknown manner (**7**, **9**, **11**, **13**). We can consider that these methylated derivatives, which are prevented from any hydroxyl group-conjugation dependency, would be less metabolized than resveratrol and potentially more bioavailable. Indeed, we have observed (unpublished results) limited metabolism of **4** after incubation with the SW480 cell line. Moreover, recent results from Lin and Ho [37,38] are in agreement with this statement, since they reported that the pharmacokinetics of (*E*)-3,5,4'-trimethoxystilbene (**3**) and (*E*)-3,5,3',4'-tetramethoxystilbene (**11**) in rat plasma are much slower than those of (*E*)-resveratrol, i.e., greater plasma exposure, longer elimination exposure, and lower clearance. In addition, the stronger effect of (*Z*)-methoxy derivatives with respect to their (*E*)-isomers is not related to the lack of an antioxidative effect (disappearance of hydroxyl groups) but is probably due to a steric-dependent mechanism leading to interference in different pathways as compared to the *trans* derivatives.

We learned of the recent work of Li et al. [39], while our work was just being completed and submitted. This work reports the effect of a pentamethoxy resveratrol derivative and the analysis of its apoptotic properties. Although from our respective analogs the (*Z*)-methoxy derivatives have both microtubule targets, our present paper does not have the same objective since our goal was the analysis of a structure–function relationship using a large series of analog (*E*)- and (*Z*)-derivatives, especially by combining experimental data and an original docking approach. Moreover, in our cell model and molecules we did not detect a strong apoptosis but a strong polyploidy (see Fig. 2).

With regard to the docking work, it is noteworthy that the adopted procedure, consisting in the extrusion of colchicine from the tubulin binding site, reconstruction of protein deficiencies (lacking in amino acid residues, hydrogen bondings, hydrogen orientations, etc.), restoring the appropriate ligand (combretastatin A-4), molecular mechanic minimization of the whole system, and, finally, submission to the AutoDock docking program [40], allowed us to obtain a model that was able to reproduce the IC₅₀ experimental values of other combretastatin analogs also reported in the literature with a high grade of precision that is, to our knowledge, the best obtained to date using docking methodology. Although the results obtained do not always coincide with the antitumoral activity, this is probably attributable to the ADME implications and not to the mechanism of actions. Then the described procedure results in a new valid approach for determining a potential tubulin ligand in the colchicine-binding site.

Table 3

Ranked comparison between binding models of compounds **1**–**14** to tubulin, cell proliferation inhibition potencies and log *D* values.

Compound ^a	Calculated tubulin IC ₅₀ (μM) ^b	Experimental IC ₅₀ range values (μM) ^c	Calculated log <i>D</i>
10	1.69	5–9	3.88
6	2.18	16–20	3.56
12	3.00	7.5–11.5	3.98
4	3.16	0.26–0.34	4.32
2	4.66	78–102	3.02
1	4.90	17–23	3.02
14	5.80	8–12	3.23
9	7.23	15–19	3.88
7	7.23	41–55	4.64
8	8.27	11–15	4.64
3	9.96	46–62	4.31
5	10.48	37–49	3.56
11	11.79	85–115	3.98
13	18.30	39–45	3.23

^a Compounds are listed in decreasing order of calculated tubulin IC₅₀ values.

^b IC₅₀ values calculated from docking and referred to tubulin inhibition.

^c Range values determined on the basis of SW480 cell growth IC₅₀ values ± SD.

5. Conclusions

- 1- The relatively weak effect of (*E*)-RSV is not exclusively attributable to its high metabolic rate and efflux, since the masking of hydroxyl groups by methylation does not significantly improve the resveratrol analog efficacy;
- 2- The *Z* configuration does not enhance resveratrol efficacy since its potency is weaker than that of the isomer with the *E* configuration;
- 3- In contrast to the preceding statement (#2), the *Z* configuration associated with the substitution of hydroxyl groups by methoxyl groups is crucial and leads to potent inhibition efficacy;
- 4- Following the preceding statement (#3) the strong efficacy of the (*Z*)-3,5,4'-trimethoxystilbene **4** would also be associated with the molecule's poor cell metabolism;
- 5- The presence of more than three methoxyl groups on the (*Z*)-resveratrol core structure does not enhance resveratrol analog efficacy but rather gives it a weaker effect;
- 6- The presence of a new hydroxyl group on tri-methylated (*Z*)-resveratrol analogs dramatically decreases the inhibitory potency;
- 7- Concerning the inhibitory mechanism, the presence of methoxyl groups, whichever resveratrol isomer (*E*)-, (*Z*)- is considered, induces cell polyploidy resulting from the blockade of cell divisions at the mitosis level;
- 8- The relationship between spatial conformations of resveratrol analogs and their effect fits quite well with docking studies where almost all of the docked structures of (*Z*)-polymethoxy isomers overlap substantially with the docked structure of combretastatin A-4 (**15**), taken as reference ligand, to bind at the colchicine–tubulin binding site, while most of the (*E*)-polymethoxy isomer counterparts fit between them but not with combretastatin.

Conflict of interest statement

The authors have no conflict of interest to declare.

Acknowledgements

This study was supported by BIVB, the Regional Council of Burgundy, the Cancer League of Côte d'Or and Jura, INSERM U866, CNRS, UMR 5260, MIUR, Ministero dell'Università e della Ricerca (PRIN 2007, Rome, Italy), and Università degli Studi di Catania, (PRA, Catania, Italy). We thank Mrs. Linda Northrup for the improvement of English.

Appendix. Supplementary material

Supplementary material associated with this article can be found in the on-line version, at doi:10.1016/j.ejmech.2010.03.024.

References

- [1] M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, et al., Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. *Science* 275 (1997) 218–220.
- [2] D. Delmas, P. Passilly-Degrace, B. Jannin, M.C. Malki, N. Latruffe, Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. *Int. J. Mol. Med.* 10 (2002) 193–199.
- [3] D. Delmas, B. Jannin, M.C. Malki, N. Latruffe, Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. *Oncol. Rep.* 7 (2000) 847–852.
- [4] D. Delmas, C. Rebe, S. Lacour, R. Filomenko, A. Athias, P. Gambert, et al., Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. *J. Biol. Chem.* 278 (2003) 1482–1490.
- [5] D. Delmas, C. Rebe, O. Micheau, A. Athias, P. Gambert, S. Grazide, et al., Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. *Oncogene* 23 (2004) 8979–8986.
- [6] S. Fulda, K.M. Debatin, Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. *Oncogene* 23 (2004) 6702–6711.
- [7] A.R. Jazirehi, B. Bonavida, Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. *Mol. Cancer Ther.* 3 (2004) 71–84.
- [8] I. Zoberi, C.M. Bradbury, H.A. Curry, K.S. Bisht, P.C. Goswami, J.L. Roti Roti, et al., Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. *Cancer Lett.* 175 (2002) 165–173.
- [9] X. Xu, H.J. Wang, P.A. Murphy, L. Cook, S. Hendrich, Daidzein is a more bioavailable soy milk isoflavone than is genistein in adult women. *J. Nutr.* 124 (1994) 825–832.
- [10] P.C. Hollman, J.M. van Trijp, M.N. Buysman, M.S. van der Gaag, M.J. Mengelers, J.H. de Vries, et al., Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. *FEBS Lett.* 418 (1997) 152–156.
- [11] M.J. Lee, Z.Y. Wang, H. Li, L. Chen, Y. Sun, S. Gobbo, et al., Analysis of plasma and urinary tea polyphenols in human subjects. *Cancer Epidemiol. Biomarkers Prev.* 4 (1995) 393–399.
- [12] D. Colin, A. Gimazane, G. Lizard, J.C. Izard, E. Solary, N. Latruffe, et al., Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. *Int. J. Cancer* 124 (2009) 2780–2788.
- [13] D. Colin, A. Lancon, D. Delmas, G. Lizard, J. Abrossinow, E. Kahn, et al., Anti-proliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. *Biochimie* 90 (2008) 1674–1684.
- [14] A.K. Marek, G. Lizard, J.C. Izard, N. Latruffe, D. Delmas, Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells. *Mol. Nutr. Food Res.* 52 (2008) 538–548.
- [15] V. Cardile, R. Chillemi, L. Lombardo, S. Sciuto, C. Spatafora, C. Tringali, Anti-proliferative activity of methylated analogues of *E*- and *Z*-resveratrol. *Z. Naturforsch. C* 62 (2007) 189–195.
- [16] M. Roberti, D. Pizzirani, D. Simoni, R. Rondanin, R. Baruchello, C. Bonora, et al., Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. *J. Med. Chem.* 46 (2003) 3546–3554.
- [17] G.R. Pettit, M.P. Grealish, M.K. Jung, E. Hamel, R.K. Pettit, J.C. Chapuis, et al., Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. *J. Med. Chem.* 45 (2002) 2534–2542.
- [18] R. Chillemi, S. Sciuto, C. Spatafora, C. Tringali, Anti-tumor properties of stilbene-based resveratrol analogues: recent results. *Nat. Prod. Commun.* 2 (2007) 1–15.
- [19] Y. Schneider, P. Chabert, J. Stutzmann, D. Coelho, A. Fougereousse, F. Gosse, et al., Resveratrol analog (*Z*)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. *Int. J. Cancer* 107 (2003) 189–196.
- [20] C. Spatafora, G. Basini, L. Baioni, F. Grasselli, A. Sofia, C. Tringali, Antiangiogenic resveratrol analogues by mild *m*-CPBA aromatic hydroxylation of 3,5-dimethoxystilbenes. *Nat. Prod. Commun.* 4 (2009) 239–246.
- [21] M. Deak, H. Falk, On the chemistry of the resveratrol diastereomers. *Monatsh. Chem.* 134 (2003) 883–888.
- [22] Atsuya Momotake, Mayuko Ud, Tatsuo Arai, Photochemical cyclisation reaction in cis-tetramethoxystilbene. *J. Photochem. Photobiol. A Chem.* 158 (2003) 7–12.
- [23] M. Gao, M. Wang, K. Miller, G. Sledge, G. Hutchins, Q. Zhang, Synthesis of radiolabelled stilbene derivative a new potential PET probe for arylhydrocarbon receptor in cancer. *Bioorg. Med. Chem. Lett.* 16 (2006) 5767–5772.
- [24] D. Koh, K.H. Park, J. Jung, Mok KH Yang, Y. Lim, Spectral assignments and reference data NMR spectra of resveratrol derivatives complete assignment of the ¹H and ¹³C. *Magn. Reson. Chem.* 39 (2001) 768–770.

- [25] N.H. Nam, Combretastatin A-4 analogues as antimetastatic antitumor agents. *Curr. Med. Chem.* 10 (2003) 1697–1722.
- [26] R.B. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, et al., Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. *Nature* 428 (2004) 198–202.
- [27] T.L. Nguyen, C. McGrath, A.R. Hermone, J.C. Burnett, D.W. Zaharevitz, B.W. Day, et al., A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. *J. Med. Chem.* 48 (2005) 6107–6116.
- [28] S.C. Lovell, I.W. Davis, W.B. Arendall 3rd, P.I. de Bakker, J.M. Word, M. G. Prisant, et al., Structure validation by Calpha geometry: phi, psi and Cbeta deviation. *Proteins* 50 (2003) 437–450.
- [29] J. Gasteiger, M. Marsili, A new model for calculating atomic charges in molecules. *Tetrahedron Lett.* 34 (1978) 3181–3184.
- [30] W. Cornell, P. Cieplak, C. Bayly, I. Gould, K. Merz Jr., D. Ferguson, et al., A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. *J. Am. Chem. Soc.* 117 (1995) 3–13.
- [31] N. Seiler, Y. Schneider, F. Gosse, R. Schleiffer, F. Raul, Polyploidisation of metastatic colon carcinoma cells by microtubule and tubulin interacting drugs: effect on proteolytic activity and invasiveness. *Int. J. Oncol.* 25 (2004) 1039–1048.
- [32] J. Erenpreisa, M. Kalejs, M.S. Cragg, Mitotic catastrophe and endomitosis in tumour cells: an evolutionary key to a molecular solution. *Cell Biol. Int.* 29 (2005) 1012–1018.
- [33] S. Mansilla, W. Priebe, J. Portugal, Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. *Cell Cycle* 5 (2006) 53–60.
- [34] P. Saiko, M. Pemberger, Z. Horvath, I. Savinc, M. Grusch, N. Handler, et al., Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. *Oncol. Rep.* 19 (2008) 1621–1626.
- [35] J.J. Heynekamp, W.M. Weber, L.A. Hunsaker, A.M. Gonzales, R.A. Orlando, L. M. Deck, et al., Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. *J. Med. Chem.* 49 (2006) 7182–7189.
- [36] J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo evidence. *Nat. Rev. Drug Discov.* 5 (2006) 493–506.
- [37] H.S. Lin, P.C. Ho, A rapid HPLC method for the quantification of 3,5,4'-trime-thoxy-trans-stilbene (TMS) in rat plasma and its application in pharmacoki-netic study. *J. Pharm. Biomed. Anal.* 49 (2009) 387–392.
- [38] H.S. Lin, C. Tringali, C. Spatafora, C. Wu, P.C. Ho, A simple and sensitive HPLC-UV method for the quantification of piceatannol analog 3,5,3',4'-tetramethoxy-trans-stilbene in rat plasma and its application for a pre-clinical pharmacokinetic study. *J. Pharm. Biomed. Anal.* 51 (2010) 679–684.
- [39] H. Li, W.K. Wu, Z. Zheng, C.T. Che, L. Yu, Z.J. Li, Y.C. Wu, K.W. Cheng, J. Yu, C. H. Cho, M. Wang, 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules. *Biochem. Pharmacol.* 78 (2009) 1224–1232.
- [40] G. Morris, D. Goodsell, R. Halliday, R. Huey, W. Hart, R. Belew, et al., Auto-mated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.* 19 (1998) 1639–1662.